These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10811138

  • 41. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [Abstract] [Full Text] [Related]

  • 42. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
    Nickerson T, Miyake H, Gleave ME, Pollak M.
    Cancer Res; 1999 Jul 15; 59(14):3392-5. PubMed ID: 10416600
    [Abstract] [Full Text] [Related]

  • 43. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM, Jackson JK, Gleave ME, Burt HM.
    Cancer Chemother Pharmacol; 2005 Sep 15; 56(3):239-47. PubMed ID: 15864591
    [Abstract] [Full Text] [Related]

  • 44. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 45. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD.
    Cancer Res; 1997 Apr 15; 57(8):1584-9. PubMed ID: 9108464
    [Abstract] [Full Text] [Related]

  • 46. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

  • 47. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M.
    Int J Oncol; 2004 Mar 01; 24(3):461-71. PubMed ID: 14767530
    [Abstract] [Full Text] [Related]

  • 48. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
    Kyprianou N, English HF, Isaacs JT.
    Cancer Res; 1990 Jun 15; 50(12):3748-53. PubMed ID: 2340521
    [Abstract] [Full Text] [Related]

  • 49. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP, Gleave ME, Cox ME.
    Prostate; 2010 Feb 01; 70(2):206-18. PubMed ID: 19790231
    [Abstract] [Full Text] [Related]

  • 50. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME.
    Neoplasia; 2001 Feb 01; 3(4):360-7. PubMed ID: 11571636
    [Abstract] [Full Text] [Related]

  • 51. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.
    Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME.
    Clin Cancer Res; 2002 Oct 01; 8(10):3276-84. PubMed ID: 12374699
    [Abstract] [Full Text] [Related]

  • 52. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2003 Mar 01; 9(3):1200-10. PubMed ID: 12631626
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R.
    Clin Cancer Res; 2002 Nov 01; 8(11):3512-9. PubMed ID: 12429642
    [Abstract] [Full Text] [Related]

  • 55. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 56. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2284-9. PubMed ID: 19080333
    [Abstract] [Full Text] [Related]

  • 57. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME.
    Neoplasia; 2005 Feb 20; 7(2):171-9. PubMed ID: 15802022
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.